USFDA4 Aug 2026, 08:59 am
Cipla Subsidiary InvaGen Receives USFDA Establishment Inspection Report
AI Summary
Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., located in Hauppauge, New York, USA, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). This report indicates the closure of the Pre-Approval Inspection (PAI) that was conducted at the facility. The intimation follows a previous disclosure on February 10th, 2026, regarding the PAI.
Key Highlights
- Cipla's subsidiary InvaGen Pharmaceuticals has received USFDA EIR.
- The EIR signifies the closure of the PAI conducted by USFDA.
- This is a positive regulatory development for the subsidiary.
- The facility is located in Hauppauge, New York, USA.
Price Impact
More from CIPLA
More in USFDA